Zenotech Laboratories Limited
BSE: ZENOTECH · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Zenotech Laboratories Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Zenotech Laboratories Limited is a Hyderabad-based pharmaceutical company specialising in the manufacturing and marketing of generic biopharmaceutical products. The firm focuses on high-value therapeutic segments including oncology, biotechnology, and gynecology, with a portfolio comprising specialty injectables and biosimilars.
Business Model
The company generates revenue through the production and sale of complex generics and biotherapeutics, leveraging a manufacturing facility that meets international regulatory standards. It operates as a subsidiary with a strategic relationship with Sun Pharmaceutical Industries Limited, which maintains a majority stake.
Growth Outlook
Growth is driven by the company's niche focus on the complex generics and biosimilars market. The firm aims to leverage its international-standard manufacturing capabilities to expand its footprint in both domestic and global markets.
Key Risks
- Regulatory Compliance. The company faces ongoing risks related to maintaining international manufacturing standards, where any failure could lead to export restrictions.
- Market Concentration. As a small-cap entity with a niche product portfolio, the company is highly susceptible to pricing pressures and competition within the oncology and biosimilar segments.
- Parent Company Dependency. The strategic relationship with Sun Pharmaceutical Industries Limited creates a dependency where changes in the parent company's strategy could significantly impact Zenotech's operations.
Start your research today
Unlock AI insights, financials, peers and live data on Zenotech Laboratories Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹40 Cr
TTM · standalone
NET PROFIT
₹7 Cr
TTM · standalone
EPS
₹1.14
TTM · standalone
RETURN ON EQUITY
7.2%
TTM · standalone
P/E
41.7x
Q4 FY26 · standalone
EV/EBITDA
14.4x
Q4 FY26 · standalone
EBITDA MARGIN
34.1%
TTM · standalone
NET PROFIT MARGIN
35.5%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Zenotech Laboratories LimitedZENOTECH | ₹286 Cr | 41.18 | 19.01 | -1.1% | 34.1% | 7.2% | 6.2% | -15.8% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Zenotech Laboratories Limited
BSE: ZENOTECH · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Zenotech Laboratories Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Zenotech Laboratories Limited is a Hyderabad-based pharmaceutical company specialising in the manufacturing and marketing of generic biopharmaceutical products. The firm focuses on high-value therapeutic segments including oncology, biotechnology, and gynecology, with a portfolio comprising specialty injectables and biosimilars.
Business Model
The company generates revenue through the production and sale of complex generics and biotherapeutics, leveraging a manufacturing facility that meets international regulatory standards. It operates as a subsidiary with a strategic relationship with Sun Pharmaceutical Industries Limited, which maintains a majority stake.
Growth Outlook
Growth is driven by the company's niche focus on the complex generics and biosimilars market. The firm aims to leverage its international-standard manufacturing capabilities to expand its footprint in both domestic and global markets.
Key Risks
- Regulatory Compliance. The company faces ongoing risks related to maintaining international manufacturing standards, where any failure could lead to export restrictions.
- Market Concentration. As a small-cap entity with a niche product portfolio, the company is highly susceptible to pricing pressures and competition within the oncology and biosimilar segments.
- Parent Company Dependency. The strategic relationship with Sun Pharmaceutical Industries Limited creates a dependency where changes in the parent company's strategy could significantly impact Zenotech's operations.
Start your research today
Unlock AI insights, financials, peers and live data on Zenotech Laboratories Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹40 Cr
TTM · standalone
NET PROFIT
₹7 Cr
TTM · standalone
EPS
₹1.14
TTM · standalone
RETURN ON EQUITY
7.2%
TTM · standalone
P/E
41.7x
Q4 FY26 · standalone
EV/EBITDA
14.4x
Q4 FY26 · standalone
EBITDA MARGIN
34.1%
TTM · standalone
NET PROFIT MARGIN
35.5%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26